Precise Bio

Precise Bio is a pioneering regenerative medicine company that specializes in bio-printed tissues and organs. The company has developed a proprietary, breakthrough 4D bio-fabricating platform that overcomes the limitations of existing extrusion and ink-jet printers. This platform enables the fabrication of clinically viable tissues and organs by 'printing' cells with single-cell resolution and spatial accuracy, resulting in complex organoid constructs with structural integrity and long-term cell viability.

Precise Bio's initial product pipeline focuses on ophthalmology and includes two cornea products developed in collaboration with Carl Zeiss Meditec, as well as a retinal implant for age-related macular degeneration. These products have demonstrated successful results in animal models. The company's ophthalmological products address global markets exceeding USD 10 billion annually. Beyond ophthalmology, Precise Bio has earlier-stage R&D programs aimed at addressing unmet needs in other medical indications where donor tissues and organs are scarce or where critical health problems can be solved using their naturally-based, hyper-accurate technology.

Precise Bio was founded in 2016 by Prof. Anthony Atala, MD, Director of the Wake Forest Institute of Regenerative Medicine (WFIRM), Prof. Shay Soker, PhD, from WFIRM, and Mr. Aryeh Batt, who developed the company's transformative laser printing technology. In September 2023, the company appointed Ori Hadomi, a veteran in the medical device sector, as its new Chairman of the Board of Directors. Precise Bio operates out of two centers, in Winston Salem, NC and Modi'in, Israel.

Key customers and partnerships

In July 2022, Precise Bio announced a partnership with Carl Zeiss Meditec, a global leader in ophthalmology. Under the agreement, Carl Zeiss Meditec invested in Precise Bio and funded the further development of Precise Bio's two cornea transplant products. Carl Zeiss Meditec also obtained exclusive worldwide commercialization rights for these products. This strategic agreement leverages Carl Zeiss Meditec's global leadership in ophthalmology and Precise Bio's innovative 4D bio-fabrication platform technology, with the goal of developing breakthrough solutions for restoring patients' eyesight.